<DOC>
	<DOC>NCT00902369</DOC>
	<brief_summary>This will be a Phase II, multi-centre study consisting of 2 parts. Part 1: Clinical Pharmacology Study (drug-drug interaction between AK106-001616 and methotrexate) Part 2: Proof of Concept Study</brief_summary>
	<brief_title>A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Diagnosis of RA (class I to III) Stable dose of methotrexate (at least 12 weeks) Pregnant or breastfeeding Abnormal screening laboratory test values considered to be clinically significant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>AK106-001616</keyword>
</DOC>